Decentralized Trials & Research Alliance

Government Agencies Emphasize the Importance of Decentralized Methodologies for Future of Clinical Research

Retrieved on: 
Wednesday, November 8, 2023
SCRS, FDA, DCT, Biomedical Advanced Research and Development Authority, Office of the National Coordinator for Health Information Technology, National Institutes of Health, Face, European Medicines Agency, Organization, BARDA, Entrepreneurship, Research, Development, DTRA, DCTS, Clinical trial, Decentralized Trials & Research Alliance, EMA, Annual general meeting, NIH, Government agency, ONC, Chairperson, Map, Government, SAN, Pharmaceutical industry, Medical device

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), a global alliance focused on the adoption of decentralized trials, today concluded its 2023 Annual Meeting, including members from biopharmaceutical companies, government agencies, research sites, healthcare organizations, patient groups, and service and technology companies.

Key Points: 
  • SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), a global alliance focused on the adoption of decentralized trials, today concluded its 2023 Annual Meeting, including members from biopharmaceutical companies, government agencies, research sites, healthcare organizations, patient groups, and service and technology companies.
  • The DTRA community learned of their strategic intentions regarding decentralized clinical trial (DCT) adoption, drivers to achieve scale with these methods, and the importance of DCT to our research ecosystem.
  • DTRA has harnessed this industry-leading expertise into creating new resources, sharing key learnings, and establishing best practices for research teams to use in implementing DCTs.
  • “Each of our Initiative outputs is available at www.dtra.org and the resources are available to all.”

Xtalks Launches Xtalks Clinical Edge Magazine: Your Gateway to the Future of Clinical Research

Retrieved on: 
Wednesday, November 1, 2023
Decentralized Trials & Research Alliance, Research, Mayo Clinic, Organization, Clinical professor, Pharmaceutical industry

TORONTO, Nov. 1, 2023 /PRNewswire-PRWeb/ -- Xtalks, a leading provider of educational webinars and digital content for the global life science, medical device, healthcare and food industries, is thrilled to announce the launch of its new magazine, Xtalks Clinical Edge. This innovative publication offers an exclusive insight into the world of clinical trials, bringing together experts, key opinion leaders and pioneers in the field to shape the future of clinical research.

Key Points: 
  • Xtalks, a division of Honeycomb Worldwide Inc., is excited to announce the launch of its groundbreaking magazine, Xtalks Clinical Edge.
  • Xtalks Clinical Edge goes beyond the norm by presenting perspectives from pharmaceutical companies, patient advocacy groups and leading clinical research organizations, fostering collaboration and knowledge-sharing within the clinical trials community.
  • Xtalks Clinical Edge is more than just a magazine; it's a platform for collaboration and innovation in the field of clinical research," said John Hughes.
  • Xtalks Clinical Edge is committed to providing valuable insights and information to professionals across the clinical research spectrum.

Buzzreach, as a startup, has become the first in Japan to join the U.S.-based Decentralized Trials & Research Alliance (DTRA).

Retrieved on: 
Thursday, October 19, 2023
Start-Up, Technology, Professional Services, Health, General Health, Pharmaceutical, Health Technology, Other Technology, Software, Internet, Clinical Trials, Decentralized Trials & Research Alliance, DTRA, Inc., Clinical trial, SNS, Patient, Multimedia, Pharmaceutical industry

Buzzreach Inc. (Headquartered in Minato-ku, Tokyo; CEO: Takateru Inokawa), a startup company, has become the first Japanese startup to join the Decentralized Trials & Research Alliance (DTRA), a Global organization dedicated to promoting decentralized clinical research.

Key Points: 
  • Buzzreach Inc. (Headquartered in Minato-ku, Tokyo; CEO: Takateru Inokawa), a startup company, has become the first Japanese startup to join the Decentralized Trials & Research Alliance (DTRA), a Global organization dedicated to promoting decentralized clinical research.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20231011227046/en/
    Willingness to Participate in Clinical Trials and Clinical Trial Information Collection pattern (Graphic: Business Wire)
    Buzzreach is engaged in the development of a clinical trial and clinical research platform business that leverages the power of technology to address the challenges of a 10-year-long drug development process, aiming to shorten the time required for drug approvals.
  • Additionally, they are involved in an SNS business connecting pharmaceutical companies and patients.

Decentralized Trials & Research Alliance Shares Patient Journey Maps Across Three Therapeutic Areas

Retrieved on: 
Tuesday, April 25, 2023
Customer success, Clinical trial, Decentralized Trials & Research Alliance, Research, DCTS, DTRA, Patient engagement in Canada, Thought, Medidata Solutions, Patient, SAN, Vaccine, Team, Pharmaceutical industry, Nursing, Medical imaging

SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA) today has announced the release of Patient Journey Maps to help researchers understand participation considerations and burden and to maximize patient inclusion, diversity, and participation in research.

Key Points: 
  • SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA) today has announced the release of Patient Journey Maps to help researchers understand participation considerations and burden and to maximize patient inclusion, diversity, and participation in research.
  • “The patient journey maps can be used as guidelines for others in the industry to find ways to truly embrace the patient perspective when it comes to decentralized clinical trials,” said Alicia Staley, Vice President of Patient Engagement at Medidata and Co-Lead of the DTRA Patient Journey Map initiative.
  • Our team delivered a unique set of patient journey maps across three different therapeutic areas, which will enhance access and engagement in clinical trials.”
    By visualizing the decision points that patients face in their treatment and clinical research experience, study teams can fully appreciate and anticipate the patient journey.
  • “We have successfully identified the patient journey for incorporating Decentralized Clinical Trials (DCTs) in clinical trials.

Everest Group Declares 'The Age of Decentralized Clinical Trials Has Begun'

Retrieved on: 
Wednesday, March 29, 2023
Research report, Travel, Decentralized Trials & Research Alliance, COVID-19, Clinical trial, Research, DCT, DCTS, DTRA, Patient, Environment, ESG, Pharmaceutical industry, DALLAS, Social

DALLAS, March 29, 2023 /PRNewswire-PRWeb/ -- Everest Group today released its latest research report on Decentralized Clinical Trials, which documents a 38% increase from 2021 to 2022 in the number of trials conducted with a decentralized and/or virtual component. Everest Group predicts that the adoption of DCTs by pharmaceutical companies will rapidly accelerate as early adopters praise the approach for putting patient experience at the forefront.

Key Points: 
  • Everest Group also joins DTRA, offering members accessibility to pioneering research on clinical technology
    DALLAS, March 29, 2023 /PRNewswire-PRWeb/ -- Everest Group today released its latest research report on Decentralized Clinical Trials, which documents a 38% increase from 2021 to 2022 in the number of trials conducted with a decentralized and/or virtual component.
  • These findings and more are detailed in the Decentralized Clinical Trials Adoption Playbook .
  • Everest Group also released today its 2023 Life Sciences Decentralized Clinical Trial Platforms State of the Market Report , which analyzes the current state of the DCT market.
  • Everest Group also announced today that it has joined the Decentralized Trials Research Alliance (DTRA) to support the organization's mission of advancing policies, research practices and new technologies to make clinical trial participation widely accessible.

Rare Disease Week 2023: Exploring Accessibility in Rare Disease Clinical Research, 4-Day Webinar Series Hosted by Xtalks

Retrieved on: 
Tuesday, March 7, 2023
Horizon Therapeutics, FSR, Health care, ICON PLC, Veronica, Partner (business rank), CHES, In-product communication, MD, MBA, Sarcoidosis, Senior, Janssen Pharmaceuticals, Disease, Enrollment, Decentralized Trials & Research Alliance, Bristol Myers Squibb, Entrepreneurship, College, Research, AVP Research Foundation, MPH, Rutgers University, Commercialization, Chairperson, IBD, Doctor of Philosophy, DCTS, Host, Patient advocacy, Gallaudet University, DAWN, Real Time Information Group, ICON, DEI, Bachelor of Science, Public affairs, Zwanzig projection operator, Nursing, Pharmaceutical industry, Birth control, Management, Honours degree, The Swift Home Service Club, Neuromuscular junction

TORONTO, March 7, 2023 /PRNewswire-PRWeb/ -- Each panel in this 4-day webinar series, whether watched individually or in totality with the other panels, will provide insights into the value of accessibility in rare disease clinical research and how sponsors, patient advocates, researchers and regulators might move from discussion to action.

Key Points: 
  • In this free webinar series, learn about myriad types of accessibility considerations for rare disease clinical research.
  • Attendees will learn how accessibility considerations fit into diversity, equity, and inclusion (DEI) plans.
  • The featured speakers will discuss best practices in accessible clinical trial design and implementation.
  • Panel 1: Is Disability Part of Your DEI Planning and Engagement in Rare Disease?

Decentralized Trials & Research Alliance Release Best Practices Rubric to Provide Framework to Evaluate DCT Processes

Retrieved on: 
Friday, February 24, 2023
Clinical trial, Ecosystem, Regulation, Drug development, Decentralized Trials & Research Alliance, Patient, DCT, SAN, DTRA, Operational definition, Patient experience, Pharmaceutical industry, Risk management, Success, Rubric

SAN DIEGO, Feb. 24, 2023 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), today announced the release of the Best Practices Rubric to aid stakeholders in evaluating decentralized clinical trial (DCT) best practices across the span of the trial lifecycle, from program planning to trial close and analysis.

Key Points: 
  • SAN DIEGO, Feb. 24, 2023 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), today announced the release of the Best Practices Rubric to aid stakeholders in evaluating decentralized clinical trial (DCT) best practices across the span of the trial lifecycle, from program planning to trial close and analysis.
  • This Rubric solves the problem: How would you assess whether a process is a DCT best practice?
  • The Rubric provides a consistent framework by which DCT practices may be evaluated.
  • Mike DeMarco shared “The DTRA Best Practices Rubric provides a consistent framework by which DCT practices may be evaluated.

CUREBASE MEDIA ALERT

Retrieved on: 
Wednesday, January 11, 2023
Hematology, Clinical trial, Patient, DTRA, Decentralized Trials & Research Alliance, Vaccine, Roche, Therapy, Pharmaceutical industry

Jane Myles , vice president of clinical trial innovation at Curebase, will be among the distinguished panelists.

Key Points: 
  • Jane Myles , vice president of clinical trial innovation at Curebase, will be among the distinguished panelists.
  • Myles has focused on improving clinical trials and patient experience for more than 25 years.
  • Her passion is driving innovation into trial design and execution to improve patient centricity and get treatments to patients faster.
  • Media contact to interview Myles:

Veristat Presents Integrated, Customized DCT Solutions at the DTRA Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Research, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, FDA, Health, Innovation, DCTS, EVP, DCT, Patient, Degenerative disease, Decentralized Trials & Research Alliance, Canavan disease, Drug development, COVID-19, Clinical trial, DTRA, Organization, Pharmaceutical industry

Offering integrated solutions for the implementation of decentralized clinical trials (DCTs) , Veristat presented the advantages of its flexible and fully customized service delivery model at the Decentralized Trials Research Alliance (DTRA) annual meeting, which took place last month in Boston.

Key Points: 
  • Offering integrated solutions for the implementation of decentralized clinical trials (DCTs) , Veristat presented the advantages of its flexible and fully customized service delivery model at the Decentralized Trials Research Alliance (DTRA) annual meeting, which took place last month in Boston.
  • "DTRAs annual conference provided the opportunity for our team to present our DCT solutions to organizations developing novel therapies which target complex and rare diseases," said Shaheen Limbada, EVP of Innovation and Strategy at Veristat.
  • In addition, Veristat has introduced its own virtual site, inclusive of patient accrual, call center intake, and protocol visit completion.
  • With more than 27 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.

Clinical Research Professionals Say Regulatory Requirements Are the Leading Barrier to Adopting Decentralized Clinical Trials

Retrieved on: 
Wednesday, November 30, 2022
CPI, Public health, Professional, Decentralized Trials & Research Alliance, CCRC, Safety, Barrier, AMC, Face, National Commission, Certify Data Systems, CCRA, Thought, Trust, FIVE, DCT, SSO, Research, Element, Credentialing, DCTS, Syneos Health, Reality, Pharmaceutical industry, Television, Online shopping, Medicine

Alexandria, Virginia, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Lack of clarity around regulatory requirements is the leading barrier to adopting decentralized clinical trials (DCTs) at the site level, according to participants at a think tank convened by the Association of Clinical Research Professionals (ACRP) .

Key Points: 
  • Alexandria, Virginia, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Lack of clarity around regulatory requirements is the leading barrier to adopting decentralized clinical trials (DCTs) at the site level, according to participants at a think tank convened by the Association of Clinical Research Professionals (ACRP) .
  • Therefore, the clinical research industry must consider the real-world experience of clinical research professionals at the site level for DCTs to be successful.
  • Designed for clinical research professionals in biopharma companies, academic, and community-based sites currently adopting the use of decentralized models.
  • The affiliated Academy of Clinical Research Professionals (The Academy) certification programs for clinical research coordinators (CCRC), clinical research associates (CCRA), and principal investigators (CPI) are accredited by the National Commission for Certifying Agencies/Institute for Credentialing Excellence.